Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction by Meira Yisraeli Salman, Alexander R. Terry, Andriy Derkach, David Nemirovsky, Kuo-Kai Chin, Yannis K. Valtis, Leora Boussi, Theresa Spivey, Wenbin Xiao, Christopher Famulare, Jenna Ciervo, Jacob M. Rowe, Martin S. Tallman, Eytan M. Stein

Get full text

Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML by Brian J. Ball, Wenbin Xiao, Gautam Borthakur, Le Xuan Truong Nguyen, Melissa Valerio, Avanthika Venkatachalam, Guido Marcucci, Anthony S. Stein, Dung Luong Thai, David N. Cook, Kyle Chan, Sonali Persaud, Ross L. Levine, Omar Abdel-Wahab, Yinon Ben-Neriah, Eytan M. Stein

Get full text

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial by Fieke W. Hoff, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L. Lin, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William G. Blum, Martha L. Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca L. Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K. Curran, Kristin L. Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja G. Marcus, Leonard Rosenberg, Brian J. Druker, Ross L. Levine, Amy Burd, Ashley O. Yocum, Uma M. Borate, Alice S. Mims, John C. Byrd, Yazan F. Madanat

Get full text